Cytokine-Based Cancer Immunotherapies Summit Boston | Hyatt Regency Boston, MA

Memo

Welcome to the only in person dedicated industry forum supporting the development of robust cytokine-based cancer immunotherapy platforms (cytokine muteins, antibody-cytokine fusion proteins (immunokines), anticancer vaccines, and cancer-directed antibodies) to deliver targeted, durable therapeutic interventions to solid tumor and hematological cancer indications. This comprehensive, drug development focused agenda will showcase the latest concepts and molecular engineering approaches being utilized by biopharma and research groups to help you overcome the challenges in: - Toxicity management - engineering selectivity, targeting and half life modulation - Optimizing the risk benefit by dose and schedule optimization - Achieving safe and acceptable delivery - Understanding the potentials for combination - Delving into the clinical data to understand the translational side You will have the opportunity to join a pre-conference workshop day exploring pre-clinical models for cytokine research and the world of cytokines in inflammatory disease, providing insight into where the world of cytokine research is going beyond oncology. Join this exclusive community of cytokine pioneers to network and learn from the leading experts in pharma, biotech and academia, as we discuss how to successfully and safely deliver cytokine therapies to a plethora of cancer indications. Across 3 content packed days, 24+ experts will converge to discuss novel cytokines, the shortfalls of these therapies and how to learn from the pitfalls of the first cytokine era – this is not one to miss! Date and Time: November 30, 2021 at 8:20 am to December 02, 2021 at 5:00 pm Prices: Conference + 2 Workshops - Drug Developer: USD 3997.00,Conference + 1 Workshop - Drug Developer: USD 3498.00,Conference Only - Drug Developer: USD 2999.00,Conference + 2 Workshops - Solution Provider: USD 4797.00,Conference + 1 Workshop - Solution Provider: USD 4198.00,Conference Only - Solution Provider: USD 3599.00,Conference + 2 Workshops - Academic: USD 3397.00,Conference + 1 Workshop - Academic: USD 2998.00,Conference Only - Academic: USD 2599.00 URLs: Tickets: https://go.evvnt.com/850076-1?pid=5569 Brochure: https://go.evvnt.com/850076-3?pid=5569 Speakers: Dario Neri, Co-CEO and CSO, Professor, Philogen and ETH Zurich, Khursheed Anwer, Chief Scientific Officer and Executive Vice President, Celsion, Christian Klein, Head Oncology Programs, Department Head Cancer Immunotherapy Discovery 3, Roche, Giovanni Abbadessa, Global Head of Oncology Early Development, and Global Project Head, peg-IL-2 (THOR-707/ SAR444245), Sanofi, Irena Adkins, Science Pharmacology Lead, SOTIO, Katherine Harris, Vice President - Discovery, TeneoBio, Hariz Hassan, Director - Clinical Development, BioNTech, Cinthia Pastuskovas, Principal Scientist, Merck and Co, Ekta Patel, Director - Translational, Xilio Therapeutics, Michael Schmidt, Chief Scientific Officer, Ankyra Therapeutics, Jamie Spangler, Assistant Professor - Biomedical, Chemical and Biomolecular Engineering, Johns Hopkins, Michael Atkins, Deputy Director, Center and William M Scholl Professor and ViceChair Department of Oncology and Professor of Medicine, Georgetown University Medical Center, Jonathan Davis, Head of Innovation, Invenra, Christoph Huber, Chief Scientific Officer, Anaevon, Valerie Pivorunas, Associate Scientific Director, Precision Medicine Immunology, AbbVie, Roberto De Luca, Head of Therapeutic Antibodies, Philogen, Ignacio Moraga, Principal Investigator, University of Dundee, Cynthia SeidelDugan, Chief Scientific Officer, Werewolf Therapeutics, Bridget O'Keeffe, Vice President, Clinical Development, OncoSec Medical, Mathias Vormehr, Director - Cancer Vaccines, BioNTech, Bradford McRae, Senior Director - Immunology Discovery, AbbVie, Carl Walkey, Senior Vice President - Corporate Development, Neoleukin Therapeutics, Reshma Singh, Associate Director, Cell Therapies Translational Medicine, Takeda, Glareh Azadi, Associate Principal Scientist, Merck and Co, Willem Overwijk, Vice President - Oncology Research, Nektar Therapeutics, Volker Schellenberger, President and Chief Executive Officer, Amunix Pharmaceuticals, Jon Wigginton, Chairman, Scientific Advisory Board and Senior Advisor, Cullinan Oncology, Nicki Panoskaltsis, Associate Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine Venue details: Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, Massachusetts, 02111, United States